- Business Wire•4 days ago
Alkermes to Present Preclinical Data on ALKS 4230 at the American Association for Cancer Research Annual Meeting
Alkermes plc today announced that preclinical data on the company’s immuno-oncology drug candidate, ALKS 4230, an engineered fusion protein designed for selective activation of the interleukin-2 receptor, will be presented at the upcoming American Association for Cancer Research Annual Meeting to be held from April 1-5, 2017 in Washington D.C.
- Business Wire•11 days ago
Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on Schizophrenia Research
Alkermes plc today announced that data for the two-month dosing option of ARISTADA® extended-release injectable suspension for the treatment of schizophrenia will be presented at the 16th International Congress on Schizophrenia Research in San Diego, March 24-28, 2017.
- Zacks•13 days ago
Alkermes plc (ALKS) announced the initiation of a new phase III study of pipeline candidate ALKS 8700.
ALKS : Summary for Alkermes plc - Yahoo Finance
Alkermes plc (ALKS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||57.81 x 300|
|Ask||64.87 x 200|
|Day's Range||58.86 - 59.77|
|52 Week Range||32.02 - 62.50|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-42.71|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|